Cargando…
An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D(3)/D(2)/D(1) dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson’s disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine...
Autores principales: | Elshoff, Jan-Peer, Cawello, Willi, Andreas, Jens-Otto, Mathy, Francois-Xavier, Braun, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382528/ https://www.ncbi.nlm.nih.gov/pubmed/25795100 http://dx.doi.org/10.1007/s40265-015-0377-y |
Ejemplares similares
-
Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
por: Cawello, Willi, et al.
Publicado: (2013) -
Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012) -
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
por: Kesayan, Tigran, et al.
Publicado: (2015) -
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]
Publicado: (2016) -
Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010)